title: C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection.
abstract: We explored the influence of the major CCR5 promoter or coding region variants as haplotypes and genotypes in a cohort of 250 chronically infected HCV patients receiving combined interferon/ ribavirin therapy. No haplotype, including the D32-bearing haplotype (G*2) reportedly associated in homozygotes with high HCV viral load (VL), showed a similar effect. Patients with genotype C/G*2 showed slightly lower median VL (p = 0.05). Neither the G*2 haplotype nor the C/G*2 genotype influenced viral dynamics during the initial 12 wk of treatment (p = 0.53). The genotype E/E was more frequent among sustained responders (15.5%) than non-responders (7.8%), and VL declined further among E/E homozygotes during the initial 12 wk of treatment, particularly those with HCV genotype 1 (p = 0.016). Differential receptor expression due to E/E homozygosity in HCV infection remains to be confirmed.
authors.affiliation: Department of Epidemiology and International Health, School of Public Health, Comprehensive Cancer Center, University of Alabama at Birmingham, 35294-0022, USA.
authors.forename: M Tevfik
authors.initials: MT
authors.lastname: Dorak
authors.forename: Gbolahan O
authors.initials: GO
authors.lastname: Folayan
authors.forename: Santosh
authors.initials: S
authors.lastname: Niwas
authors.forename: Dirk J
authors.initials: DJ
authors.lastname: van Leeuwen
authors.forename: Leland J
authors.initials: LJ
authors.lastname: Yee
authors.forename: Jianming
authors.initials: J
authors.lastname: Tang
authors.forename: Richard A
authors.initials: RA
authors.lastname: Kaslow
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D006239:Haplotypes; D016174:Hepacivirus / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011401:Promoter Regions, Genetic; D012367:RNA, Viral / Q000097:blood; D054390:Receptors, CCR2; D019713:Receptors, CCR5 / Q000235:genetics*; D019707:Receptors, Chemokine / Q000235:genetics*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D014766:Viremia / Q000188:drug therapy / Q000235:genetics / Q000276:immunology
chemical_list: D000998:Antiviral Agents; C515334:CCR2 protein, human; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D054390:Receptors, CCR2; D019713:Receptors, CCR5; D019707:Receptors, Chemokine; D011994:Recombinant Proteins; D012254:Ribavirin